Effect of Preoperative Stellate Ganglion Block on Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting

NCT07271615 | Recruiting

• 1 other identifier: KY20250716
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this study is to determine the feasibility of preoperative stellate ganglion block in reducing the incidence of postoperative atrial fibrillation in patients undergoing CABG.

Conditions

Adult Patients Undergoing CABG

Outcome Measures

Primary Outcomes (1)

• postoperative atrial fibrillation（POAF）

  within 7 days postoperatively

Secondary Outcomes (6)

• cumulative time spent in postoperative atrial fibrillation

  within 7 days postoperatively

• the need for antiarrhythmic medications to treat postoperative atrial fibrillation

  within 7 days postoperatively

• the need for systemic anticoagulation due to postoperative atrial fibrillation

  within 7 days postoperatively

• the need for postoperative electrical cardioversion

  within 7 days postoperatively

• the duration of postoperative in-hospital stay

  duration of postoperative hospital stay

Study Arms (2)

Control group（C group）

NO INTERVENTION

the best available treatment without block (usual care)

Stellate Ganglion Block（S group）

OTHER

Ultrasound-guided stellate ganglion block with ropivacaine

Procedure: Stellate Ganglion Block

Interventions

Stellate Ganglion Block PROCEDURE

Ultrasound-guided stellate ganglion block with ropivacaine

Stellate Ganglion Block（S group）

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• more than 18 years old
• undergoing CABG
• Provide informed consent

You may not qualify if:

• History of prior cardiac surgery or atrial fibrillation ablation;
• Emergency coronary artery bypass grafting (CABG);
• Concomitant cardiac procedures (e.g., congenital heart disease repair, left ventricular reconstruction, valve surgery, or aortic surgery);
• Critical preoperative status requiring mechanical or pharmacological support before CABG;
• Left ventricular ejection fraction (LVEF) \<35%;
• History of atrial fibrillation (defined as a supraventricular tachyarrhythmia characterized by rapid and irregular atrial electrical activity);
• Significant mitral valve disease (mitral valve area \<1.5 cm² or regurgitant jet area \<4 cm²), significant aortic valve disease (valve area \<1.5 cm² or regurgitant jet-to-left ventricular outflow tract ratio \>25%);
• Severe left atrial enlargement (left atrial anteroposterior diameter \>55 mm);
• Poorly controlled hyperthyroidism;
• Conditions requiring radiotherapy, chemotherapy, or long-term hormonal therapy;
• Patients with known clinical contraindications to stellate ganglion block (SGB).

Sponsors & Collaborators

• Xijing Hospital: lead

Study Sites (1)

Xijing Hospital

Xi'an, Shaanxi, 710032, China

RECRUITING

Central Study Contacts

Chong Lei

CONTACT

18629011362; crystalleichong@126.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD，phD

Study Record Dates

• First Submitted: November 26, 2025
• First Posted: December 9, 2025
• Study Start: November 19, 2025
• Primary Completion (Estimated): May 31, 2026
• Study Completion (Estimated): July 31, 2026
• Last Updated: December 9, 2025

Record last verified: 2025-12

Locations

CN (1)